By Dominic Chopping Novo Nordisk launched a bid valued at up to $9 billion for obesity-drug developer Metsera, hoping to trump an already agreed-on deal Pfizer made for the U.S. company last...
Novo Nordisk Seeks to Outmuscle Pfizer With Up to $9 Billion Bid for Metsera -- 2nd Update